BioLife Solutions to Present at Third Annual Marcum MicroCap Conference
PR Newswire
BOTHELL, Wash.

BOTHELL, Wash., May 12, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that management will present at the Third Annual Marcum MicroCap Conference in New York City on May 29, 2014 at the Grand Hyatt New York. Since 2012, the Marcum conference has introduced investors to promising undiscovered companies with a market capitalization of under $500 million. As part of the conference, BioLife will participate in one-on-one meetings with investors and other companies.

Mike Rice, BioLife's President & CEO, said, "The Marcum conference is a great forum for companies like BioLife. I look forward to presenting an investment thesis based on our potential growth as an embedded life science tools provider. Our strategic markets of biobanking, drug discovery, and regenerative medicine have significant unmet needs in the biopreservation and transportation of cells and tissues used in research and clinical applications. Our tools portfolio has demonstrated great success in extending yield and viability of biologics and we are well configured to participate in the growth of key vertical markets." 

BioLife will present growth opportunities for its proprietary, clinical grade biopreservation media products including CryoStor® freeze media and HypoThermosol® shipping and storage medium, specialty contract manufacturing services, and biologistexsm cloud-based monitoring and management portal for EVO™ smart, controlled temperature shipping containers for cells and tissues.

Presentation time and details:

  • Location: Grand Hyatt New York (109 E 42nd Street, New York, NY 10017)
  • Date: May 29, 2014
  • Time: 1:30PM2:00PM ET
  • Room: Morosco

The conference will feature the following presentation tracks:

  • Healthcare and Life Sciences
  • Energy and Natural Resources
  • Retail and Consumer Products
  • Industrials
  • Technology, Media and Telecommunications
  • Financial and Asset Management Services

To schedule a one-on-one meeting with management, please contact Daphne Taylor by phone, (425) 402-1400, or email at dtaylor@biolifesolutions.com.

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. Launched in 2012, the annual Marcum MicroCap Conference features presentations by CEOs and CFOs from promising high-growth companies, the top picks by some of the most astute analysts following small caps, and thoughtful commentary on successful investment strategies and sectors. This invitation-only event attracts top fund managers and qualified high net worth investors who focus on small cap equities. One-on-one meetings are available for company management teams and qualified investors.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning our potential revenue growth and market expansion. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations



Daphne Taylor



Senior Vice President, Chief Financial Officer



(425) 402-1400



dtaylor@biolifesolutions.com






SOURCE BioLife Solutions, Inc.

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance